Quratis has applied to conduct Phase 2 clinical trials of its tuberculosis (TB) vaccine for adults in Korea, the Korea Biomedical Review reported on Friday.
The company was founded following an extensive joint research project between Yonsei University Health System and the US-based Infectious Disease Research Institute (IDRI). Earlier this year, the research institute and Quratis signed a technology transfer contract for TB.
The company plans to build a facility to produce and sell the vaccine to the global market, including Korea, by 2018, after the Phase 2 clinical trials.
While there is a BCG vaccine designed to protect against severe forms of TB, the vaccine is given to infants during the first four weeks after birth and there are no vaccines in Korea that treat adults. Adults become less protected by BCG with age.
The new vaccine, ID93+GLA-SE, was developed by IDRI by fusing selected protein antigens through analysis of bioinformatics of Mycobacterium tuberculosis worldwide. The recommended dose is for adults to receive three doses, so as to induce protective immunity against TB.
Virbac expands presence in Japan with Sasaeah acquisition
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
US CDC advisory committee backs Valneva's chikungunya vaccine
Takeda and Biological E. Limited join forces to combat global dengue threat
SK bioscience 'SKYTyphoid' receives WHO prequalification certification
ImmunityBio advances cancer vaccine trial for Lynch syndrome participants
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
Ultimovacs gains EMA Orphan Drug status for UV1 cancer vaccine in mesothelioma